2: Twice the Targets, A Newly Approved Bispecific Enters the Myeloma Arena

Regeneron has officially entered the multiple myeloma arena with FDA approval of Lynozyfic, a BCMA-targeted bispecific antibody for patients who’ve exhausted standard therapies. In this episode, we break down what Lynozyfic is, how it works, and how it stacks up against competitors.